Drug-loaded embolism microalgae ball for resisting liver cancer as well as preparation method and application of drug-loaded embolism microalgae ball
The drug-loaded microalgae prepared through microfluidic control technology solves the problems of uneven particle size and biocompatibility of existing hepatic arterial chemoembolization materials, achieving effective controlled release of drugs and improving the therapeutic effect of liver cancer.
Patent Information
- Application Number
- CN202410967016.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing hepatic arterial chemoembolizing materials have problems such as uneven particle size and easy to break, which leads to poor treatment effects or causes complications. It is difficult to extract and standardize Chinese medicine ingredients, which affects drug activity.
Microfluidic control technology is used to mix microalgae cells with drugs, polyvinyl alcohol, polydimethylsiloxane and curing agent to form a double emulsion, and uniform particle size drug-loaded microalgae balls are prepared to realize drugs through surface electrostatic action. Adsorption and sustained release.
The prepared drug-loaded microalgae balls have uniform particle size, good biocompatibility and stability, avoiding the problem of blood vessel blockage, achieving controlled release of drugs, enhancing the therapeutic effect, and reducing damage to normal tissues.
Smart Images

Figure CN118987262A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical materials, and specifically relates to a drug-loaded embolic microalgae ball for anti-liver cancer, and a preparation method and application thereof. Background Art
[0002] Hepatic arterial chemoembolization is a non-surgical tumor interventional treatment method commonly used in clinical practice. It usually injects embolic materials into the blood supply arteries of tumor tissue to block blood supply, inhibit tumor growth, and release high concentrations of chemotherapeutic drugs locally to kill tumor cells. This method has the advantages of minimally invasive, safe, targeted, high treatment efficiency and low toxicity. However, existing embolic materials have certain limitations, such as drug-loaded embolic microspheres. Beads have problems such as uneven particle size and easy breakage in blood vessels, which may lead to poor treatment effect or other complications. Therefore, it is necessary to optimize the shape of embolic materials and improve the uniformity of particle size of embolic materials.
[0003] There are various embolic materials used in hepatic artery chemoembolization, including traditional iodized oil, gelatin, sodium alginate, microsphere materials, etc. Among them, microspheres are suitable for selective embolization of blood vessels with specific inner diameters and the entire cross-section of easily occluded blood vessels, and have a more reliable embolization effect. Microspheres can also be used as a drug delivery system to achieve sustained release of drugs at the tumor site, with good therapeutic effects.
[0004] The Chinese patent document with publication number CN102585258A discloses a gelatin embolic microsphere and its preparation method and application. In the invention, a gelatin aqueous solution is first prepared, and then the gelatin aqueous solution is added to the oil phase containing an emulsifier, stirred, cooled, stirred again, and allowed to stand to allow the formed microspheres to settle; then the oil phase is removed by pouring, and the oil phase remaining on the surface of the microspheres is repeatedly washed with acetone to filter out the microspheres; finally, the obtained microspheres are added to a crosslinking agent aqueous solution and stirred, and the gelatin embolic microspheres are obtained after reaction and washing. The gelatin embolic microspheres are regular spherical, and their degradation time and elasticity are more suitable for clinical applications. However, animal-derived gelatin may cause allergic reactions, and the multiple steps in the preparation process increase costs, time, and the risk of errors.
[0005] The Chinese patent document with the publication number CN110354299A discloses a Chinese medicine embolic microsphere for interventional treatment of advanced liver cancer and its preparation method, which is composed of the following components in mass percentage: 75.48% to 81.99% of Bletilla polysaccharide, 0.5% to 1.5% of sodium cantharidinate, 2.5% to 3.0% of lecithin, 0.01% to 0.02% of cholesterol, and 15% to 20% of 1,2-propylene glycol, and the mass percentage of the above components is 100%. The Chinese medicine embolic microsphere is prepared by using Bletilla polysaccharide as the skeleton material, embedding sodium cantharidinate nano-flexible liposomes, and then emulsifying, cross-linking and sterilizing. However, the extraction and standardization of Chinese medicine components are difficult, which may lead to batch inconsistency problems, and the stability of the active substance in storage and in vivo may affect the activity of the drug. Summary of the invention
[0006] The present invention provides a method for preparing drug-loaded embolic microalgae balls for treating liver cancer. The drug-loaded embolic microalgae balls prepared by the method have uniform particle size distribution and good biocompatibility, can solve the problems of uneven distribution and ectopic embolism of existing embolic materials in treating liver cancer, and improve the treatment effect.
[0007] The specific technical solutions adopted are as follows:
[0008] A method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer comprises the following steps:
[0009] (1) mixing microalgae cells and drugs to prepare a drug-loaded microalgae cell solution; the microalgae cells are Chlorella pyrenoidosa cells or Synechocystis cells; the microalgae cells may be common microalgae cells or freeze-dried microalgae cells;
[0010] (2) Using a drug-loaded microalgae cell solution containing polyvinyl alcohol as the inner phase solution, a mixed solution containing polydimethylsiloxane, dimethyl silicone oil, and a curing agent as the middle phase solution, and a polyvinyl alcohol solution as the outer phase solution, microfluidic technology is used to adjust the flow rates of the inner phase solution, the middle phase solution, and the outer phase solution to prepare the drug-loaded embolic microalgae ball for anti-liver cancer.
[0011] After the microalgae cells and drugs are mixed, the microalgae cells adsorb the drugs through surface electrostatic effects, thereby achieving the loading effect. The microalgae cells provide a biocompatible and biodegradable platform that can be used for drug loading and sustained release. At the same time, the microalgae cells have a high surface area to volume ratio, which helps to increase the drug loading and controlled release capacity of the drug and prolong the drug action time. Chlorella cells or Synechocystis cells grow quickly and are easy to culture on a large scale. Microalgae cells can be designed into specific shapes and sizes to meet different drug delivery requirements. In addition, their cell walls are thinner, making it easier to achieve drug loading and release.
[0012] The drug includes carrelizumab SHR-1210 or polypeptide antagonist AUNP-12.
[0013] Preferably, when the microalgae cells are freeze-dried microalgae cells, the mass ratio of the microalgae cells to the drug is 0.1-2:1.
[0014] Optionally, in step (2), polyvinyl alcohol is added to the drug-loaded microalgae cell solution of step (1) to obtain an inner phase solution, and the concentration of polyvinyl alcohol in the inner phase solution is controlled to be 0.2-10 wt %.
[0015] In the intermediate phase solution, the mass ratio of polydimethylsiloxane, dimethyl silicone oil and curing agent is 1:0.5-5:0.05-5; the mass concentration of polydimethylsiloxane is 3-30wt%; the curing agent can be selected from silicone elastomer curing agent or phenyl (2,4,6-trimethylbenzoyl) lithium phosphate and the like.
[0016] In the external phase solution, the concentration of polyvinyl alcohol is 0.2-10 wt %.
[0017] Specifically, in the microfluidic process, the inner phase solution and the middle phase solution are premixed by using a T-shaped channel, and then the premixed solution is mixed with the outer phase solution by using a T-shaped channel, the flow rate of the inner phase solution is 1-100 μL / h, the flow rate of the middle phase solution is 2-200 μL / h, and the flow rate of the outer phase solution is 300-2000 μL / h; the obtained double emulsion droplets are collected in a 0.2-10wt% polyvinyl alcohol aqueous solution to obtain the drug-loaded embolic microalgae spheres for anti-liver cancer. The use of polyvinyl alcohol aqueous solution to collect double emulsion droplets can ensure that unnecessary fusion occurs between the collected double emulsion droplets. In addition, under the specific process and parameters of the present invention, the obtained product microspheres have better stability, are not easy to break in blood vessels, and can form microspheres of more uniform size.
[0018] The present invention also provides the drug-loaded embolic microalgae spheres for anti-liver cancer prepared by the preparation method of the drug-loaded embolic microalgae spheres for anti-liver cancer. The particle size of the drug-loaded embolic microalgae spheres for anti-liver cancer is 50-200 μm, preferably 80-120 μm.
[0019] The present invention also provides the use of the drug-loaded embolization microalgae spheres for anti-liver cancer in the preparation of liver cancer treatment products.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] (1) The method of the present invention uses microfluidic technology and a specific three-phase system to accurately control the particle size of the drug-loaded embolic microalgae spheres. The obtained drug-loaded embolic microalgae spheres have uniform particle size and good sphericity, thereby avoiding the problem of vascular blockage caused by uneven particle size. In addition, the drug-loaded embolic microalgae spheres serve as drug carriers to achieve controlled release of drugs, increase local drug concentration, and enhance therapeutic effects.
[0022] (2) The drug-loaded embolic microalgae spheres provided by the present invention have good biocompatibility, reducing damage to normal tissues. After the drug release is completed, the drug-loaded embolic microalgae spheres can be biodegraded, reducing the risk of long-term presence in the body, and have a good therapeutic effect on liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a morphological picture of the drug-loaded embolic microalgae sphere for anti-liver cancer prepared in Example 1.
[0024] Figure 2 This is the drug release kinetics curve of the drug-loaded embolic microalgae spheres for anti-liver cancer prepared in Example 1.
[0025] Figure 3 This is a graph showing the results of a hemolysis experiment of the drug-loaded embolic microalgae spheres for anti-liver cancer prepared in Example 1.
[0026] Figure 4 These are the results of blood biochemical analysis of different animal model groups (Model group, lodine oil group, IRE group, VA group; IRE+VA group). BUN represents urea nitrogen; CRE represents creatinine; ALT represents alanine aminotransferase; AST represents aspartate aminotransferase; and D-Bil represents direct bilirubin.
[0027] Figure 5 These are the histopathological HE staining results of different animal model groups (Model group, lodine oil group, IRE group, VA group; IRE+VA group).
[0028] Figure 6 Statistical chart of tumor size in different animal model groups (Model group, IRE group, VA group; IRE+VA group).
[0029] Figure 7 These are the HE staining results and Ki67 immunohistochemistry results of different animal model groups (Model group, IRE group, VA group; IRE+VA group).
[0030] Figure 8 These are in vivo imaging images of different animal model groups (Model group, IRE group, VA group; IRE+VA group).
[0031] Fig. 9Angiographic images of the embolic effects of microalgae spheres loaded with drugs at different concentrations.
[0032] In the figures, * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001. DETAILED DESCRIPTION
[0033] The present invention is further illustrated below in conjunction with the examples and accompanying drawings. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The operating methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0034] The rat hepatocellular carcinoma (N1S1) cells used in the examples were purchased from ATCC China Cell Bank - ATCC Cell Resource Center, the polypeptide antagonist AUNP-12 was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., and the carrelizumab SHR-1210 was provided by Jiangsu Hengrui Medicine Co., Ltd.
[0035] Example 1
[0036] (1) Cultivating pyrenoid Chlorella cells using BG11 medium (BG11 medium purchased from Shanghai Guangyu Biotechnology Co., Ltd.), culturing for a certain period of time under light at 25°C (changing the medium every 15 days, replacing 1 / 3 of the total volume of the culture medium), centrifuging the pyrenoid Chlorella cell solution at 3000g for 10 minutes, collecting the pyrenoid Chlorella cells, then washing them with deionized water for 3 times, and freeze-drying them to obtain freeze-dried pyrenoid Chlorella cells; mixing 0.5 mg of freeze-dried pyrenoid Chlorella cells and 0.5 mg of polypeptide antagonist AUNP-12 in water to achieve drug loading, thereby preparing a drug-loaded microalgae cell solution;
[0037] (2) preparing the required fluid solutions of each phase: adding polyvinyl alcohol to the drug-loaded microalgae cell solution of step (1) to obtain an inner phase solution, and controlling the concentration of polyvinyl alcohol in the inner phase solution to be 5 wt %; adding polydimethylsiloxane, dimethyl silicone oil, and SYLGARD in a mass ratio of 1:2.33:0.33; TM 184 silicone elastomer curing agent (Article No. 1024001) was dissolved in distilled water to prepare an intermediate phase solution, in which the concentration of polydimethylsiloxane was 27.2wt%; a polyvinyl alcohol solution with a concentration of 5wt% was used as the external phase solution; the aqueous phase solution was filtered with a 0.45μm filter before use to prevent blocking of the microchannel;
[0038] (3) Pure water is first introduced into each microfluidic channel, and the required solution is then introduced after the chip is filled with pure water. The external phase fluid, the intermediate phase fluid, and the internal phase fluid prepared in the above steps are respectively injected into the glass capillary microfluidic chip through a microinjection pump; specifically, during the microfluidic process, the internal phase solution and the intermediate phase solution are premixed using a T-channel, and then the premixed solution is mixed with the external phase solution using a T-channel, the flow rate of the internal phase solution is 25 μL / h, the flow rate of the intermediate phase solution is 50 μL / h, and the flow rate of the external phase solution is 1000 μL / h; the double emulsion droplets obtained by the microfluidic process are collected and collected in a 1wt% polyvinyl alcohol aqueous solution to obtain the drug-loaded embolic microalgae sphere for anti-liver cancer.
[0039] Example 2
[0040] The preparation method of the drug-loaded embolic microalgae spheres for anti-liver cancer in this embodiment is different from that in Example 1 only in that 1 mg of freeze-dried Synechocystis cells and 0.5 mg of carrelizumab SHR-1210 are mixed in water to achieve drug loading to prepare a drug-loaded microalgae cell solution.
[0041] Sample analysis
[0042] The drug-loaded embolic microalgae spheres for anti-liver cancer obtained in Example 1 were characterized and their performance analyzed as follows:
[0043] (1) Morphological characterization
[0044] The optical image of the drug-loaded embolic microalgae sphere obtained by optical microscopy is as follows: Figure 1 As shown, it can be seen that the particle size is evenly distributed at about 100 μm, the sphericity is good, and the size is uniform. This shows that the method of the present invention can produce microalgae balls with consistent physical properties, which is beneficial to drug delivery and embolization effects.
[0045] (2) Drug release kinetics
[0046] The drug release kinetics experiment was conducted in phosphate buffer at 37°C by simulating the release environment in vivo. Figure 2 As shown in the figure, the drug release kinetics curve shows that the drug-loaded embolic microalgae spheres can control the drug release rate in a simulated in vivo environment and show good sustained-release properties, which helps to maintain effective drug concentrations at the tumor site and prolong the drug action time. (3) Biocompatibility and safety evaluation
[0047] The effect of drug-loaded embolic microalgae spheres on blood cells was evaluated by hemolysis test. Figure 3 As shown in the figure, the results of the hemolysis test showed that the effect of the drug-loaded embolic microalgae spheres on blood cells was within a safe range and did not cause significant hemolysis, indicating that it had good biocompatibility.
[0048] The drug-loaded embolic microalgae balls were injected into animal models to observe their distribution, metabolism and potential toxicity in vivo. Blood biochemical analysis and histopathological examination were used to evaluate the effects of the microalgae balls on major organs (such as heart, liver, spleen, lungs, and kidneys). The animal models were divided into five groups: Model: blank control group; lodine oil: iodine oil group, using traditional iodine oil for embolization; IRE: simple irreversible electroporation treatment group; VA: treatment group using the drug-loaded embolic microalgae balls for anti-liver cancer prepared in Example 1; IRE+VA: a combined treatment group of irreversible electroporation and the drug-loaded embolic microalgae balls for anti-liver cancer prepared in Example 1.
[0049] Figure 4 In the table, BUN denotes urea nitrogen, CRE denotes creatinine, ALT denotes alanine aminotransferase, AST denotes aspartate aminotransferase, and D-Bil denotes direct bilirubin. Figure 4 and Figure 5 The results of blood biochemical analysis and histopathological examination showed that the drug-loaded embolic microalgae balls had little effect on major organs such as the heart, liver, spleen, lungs, and kidneys after injection, and did not cause obvious pathological changes, further confirming its biological safety.
[0050] The results of section staining showed that none of the organs observed showed obvious pathological damage or inflammatory response, indicating that the microalgae balls have good biocompatibility. In addition, no abnormal cell proliferation or tissue structural changes were observed, further confirming that the microalgae balls do not cause significant tissue reactions or damage in vivo.
[0051] (4) Evaluation of the therapeutic efficacy of liver cancer
[0052] An animal model of liver cancer was established, and the animal model was divided into four groups: Model: blank control group; IRE: simple irreversible electroporation treatment group; VA: treatment group using the drug-loaded embolic microalgae spheres for anti-liver cancer prepared in Example 1; IRE+VA: combined treatment group of irreversible electroporation and the drug-loaded embolic microalgae spheres for anti-liver cancer prepared in Example 1, to evaluate the efficacy of drug-loaded embolic microalgae spheres in the treatment of liver cancer. The drug-loaded embolic microalgae spheres were injected into the tumor site through the hepatic artery, and the growth of the tumor was monitored regularly by imaging techniques (such as CT, MRI or ultrasound). At the same time, the pathological changes of the tumor tissue and the distribution of the drug-loaded embolic microalgae spheres were evaluated by HE staining and immunohistochemical analysis. In addition, the survival period of the treated animals was observed to evaluate the therapeutic effect.
[0053] Imaging technology monitoring of tumor growth showed that simple IRE treatment and drug-loaded microalgae sphere embolization had a significant tumor inhibitory effect compared with the model group ( Figure 6 and Figure 7). The combined treatment group of IRE combined with drug-loaded embolic microalgae spheres showed a more significant tumor inhibition effect and was able to effectively inhibit tumor growth. This shows the superiority of combined treatment. The angiography results after the interventional injection of drug-loaded embolic microalgae spheres showed that the microalgae spheres could effectively achieve vascular embolization, block the blood supply of the tumor, and thus inhibit tumor growth.
[0054] (5) Evaluation of in vivo retention and embolization effect
[0055] The retention and dynamic behavior of the drug-loaded embolic microalgae spheres in vivo were evaluated by observation at different time points, and the retention time of the drug-loaded embolic microalgae spheres in vivo was monitored by fluorescence imaging technology. Figure 8 As shown in the figure, the aggregation of microalgae in liver tumors was still observed 14 days after administration, and the fluorescence intensity did not change much, indicating that its embolization effect was good. Different concentrations of drug-loaded embolization microalgae balls were injected into the animal body by interventional methods, with an injection rate of 0.1mL / min and an injection volume of 0.2mL, and angiography was performed. The results are shown in the figure. Fig. 9 As shown in the figure, a significant vascular embolization effect was observed. The angiography results after the injection of different concentrations of drug-loaded embolic microalgae balls by interventional methods showed that as the concentration of drug-loaded embolic microalgae balls increased, the embolization effect also increased. At a concentration of 10 mg / ml and higher, the microalgae balls can effectively achieve vascular embolization, block the blood supply of the tumor, and thus inhibit tumor growth.
[0056] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer, characterized in that: The following steps are involved: (1) mixing microalgae cells and drugs to prepare a drug-loaded microalgae cell solution; The microalgae cells are Chlorella pyrenoidosa cells or Synechocystis cells; (2) Using a drug-loaded microalgae cell solution containing polyvinyl alcohol as the inner phase solution, a mixed solution containing polydimethylsiloxane, dimethyl silicone oil, and a curing agent as the middle phase solution, and a polyvinyl alcohol solution as the outer phase solution, microfluidic technology is used to adjust the flow rates of the inner phase solution, the middle phase solution, and the outer phase solution to prepare the drug-loaded embolic microalgae ball for anti-liver cancer.
2. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: The drug includes carrelizumab SHR-1210 or polypeptide antagonist AUNP-12.
3. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: When the microalgae cells are freeze-dried microalgae cells, the mass ratio of the microalgae cells to the drug is 0.1-2:
1.
4. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: In step (2), polyvinyl alcohol is added to the drug-loaded microalgae cell solution of step (1) to obtain an inner phase solution, and the concentration of polyvinyl alcohol in the inner phase solution is controlled to be 0.2-10 wt%.
5. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: In the intermediate phase solution, the mass ratio of polydimethylsiloxane, dimethyl silicone oil and curing agent is 1:0.5-5:0.05-5; the mass concentration of polydimethylsiloxane is 3-30wt%.
6. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: In the external phase solution, the concentration of polyvinyl alcohol is 0.2-10 wt %.
7. The method for preparing drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 1, characterized in that: In the microfluidic process, the inner phase solution and the middle phase solution are premixed by using a T-shaped channel, and then the premixed solution is mixed with the outer phase solution by using the T-shaped channel. The flow rate of the inner phase solution is 1-100 μL / h, the flow rate of the middle phase solution is 2-200 μL / h, and the flow rate of the outer phase solution is 300-2000 μL / h. The obtained double emulsion droplets are collected in a 0.2-10wt% polyvinyl alcohol aqueous solution to obtain the drug-loaded embolic microalgae ball for anti-liver cancer.
8. The drug-loaded embolic microalgae spheres for use in preventing liver cancer are prepared according to the method for preparing drug-loaded embolic microalgae spheres for use in preventing liver cancer according to any one of claims 1 to 7.
9. Use of the drug-loaded embolic microalgae spheres for anti-liver cancer according to claim 8 in the preparation of liver cancer treatment products.
Citation Information
Patent Citations
Integrated dual emulsion particle generator and processing method thereof
CN106492716A
Core-shell type pre-charged chemotherapy medicine embolization microsphere and preparation method thereof
CN108721684A
Dissoluble microneedle containing active microalgae, microneedle patch, preparation method and application
CN114557954A
A Microfluidic device for analyzing chemotaxis of microalgae and Method for analyzing chemotaxis by using the same
KR1020170089263A
Oral Anti-radiation microalgae-nanoparticle compound preparation, and preparation method and use thereof
US20240122874A1
Cited By
Application of chemotherapeutic drug-microalgae embolism agent in preparation of drug for treating tumors by arterial embolism
CN121668337A
